Your browser doesn't support javascript.
loading
Linking the heart and the brain: Neurodevelopmental disorders in patients with catecholaminergic polymorphic ventricular tachycardia.
Lieve, Krystien V V; Verhagen, Judith M A; Wei, Jinhong; Bos, J Martijn; van der Werf, Christian; Rosés I Noguer, Ferran; Mancini, Grazia M S; Guo, Wenting; Wang, Ruiwu; van den Heuvel, Freek; Frohn-Mulder, Ingrid M E; Shimizu, Wataru; Nogami, Akihiko; Horigome, Hitoshi; Roberts, Jason D; Leenhardt, Antoine; Crijns, Harry J G; Blank, Andreas C; Aiba, Takeshi; Wiesfeld, Ans C P; Blom, Nico A; Sumitomo, Naokata; Till, Jan; Ackerman, Michael J; Chen, S R Wayne; van de Laar, Ingrid M B H; Wilde, Arthur A M.
Afiliação
  • Lieve KVV; AMC Heart Center, Department of Clinical and Experimental Cardiology, Academic Medical Center, Amsterdam, The Netherlands.
  • Verhagen JMA; Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Wei J; The Libin Cardiovascular Institute of Alberta, Department of Physiology and Pharmacology, University of Calgary, Calgary, Alberta, Canada.
  • Bos JM; Department of Cardiovascular Diseases, Division of Heart Rhythm Services, Mayo Clinic, Rochester, Minnesota, Department of Pediatric and Adolescent Medicine, Division of Pediatric Cardiology, Mayo Clinic, Rochester, Minnesota, and Department of Molecular Pharmacology & Experimental Therapeutics,
  • van der Werf C; AMC Heart Center, Department of Clinical and Experimental Cardiology, Academic Medical Center, Amsterdam, The Netherlands.
  • Rosés I Noguer F; Department of Cardiology, Royal Brompton Hospital, London, United Kingdom.
  • Mancini GMS; Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Guo W; The Libin Cardiovascular Institute of Alberta, Department of Physiology and Pharmacology, University of Calgary, Calgary, Alberta, Canada.
  • Wang R; The Libin Cardiovascular Institute of Alberta, Department of Physiology and Pharmacology, University of Calgary, Calgary, Alberta, Canada.
  • van den Heuvel F; Department of Pediatric Cardiology, Beatrix Children's Hospital, University Medical Center Groningen, Groningen, The Netherlands.
  • Frohn-Mulder IME; Department of Pediatric Cardiology, Sophia Children's Hospital, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Shimizu W; Department of Cardiovascular Medicine, Nippon Medical School, Tokyo, Japan; Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.
  • Nogami A; Cardiovascular Division, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
  • Horigome H; Cardiovascular Division, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
  • Roberts JD; Section of Cardiac Electrophysiology, Division of Cardiology, Department of Medicine, Western University, London, Ontario, Canada.
  • Leenhardt A; CNMR Maladies Cardiaques Héréditaires Rares, Hôpital Bichat, Université Paris Diderot, Sorbonne Paris Cité, Paris, France, and AP-HP, Service de Cardiologie, Hôpital Bichat, Paris, France.
  • Crijns HJG; Department of Cardiology, CARIM School for Cardiovascular Diseases, Faculty of Health, Medicine, and Life Sciences, Maastricht University, Maastricht, The Netherlands.
  • Blank AC; Department of Pediatric Cardiology, Wilhelmina Children's Hospital, University Medical Center, Utrecht, The Netherlands.
  • Aiba T; Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.
  • Wiesfeld ACP; Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Blom NA; AMC Heart Center, Department of Clinical and Experimental Cardiology, Academic Medical Center, Amsterdam, The Netherlands; Department of Pediatric Cardiology, Leiden University Medical Center, Leiden, The Netherlands.
  • Sumitomo N; Department of Pediatric Cardiology, Saitama Medical University International Medical Center, Saitama, Japan.
  • Till J; Department of Cardiology, Royal Brompton Hospital, London, United Kingdom.
  • Ackerman MJ; Department of Cardiovascular Diseases, Division of Heart Rhythm Services, Mayo Clinic, Rochester, Minnesota, Department of Pediatric and Adolescent Medicine, Division of Pediatric Cardiology, Mayo Clinic, Rochester, Minnesota, and Department of Molecular Pharmacology & Experimental Therapeutics,
  • Chen SRW; The Libin Cardiovascular Institute of Alberta, Department of Physiology and Pharmacology, University of Calgary, Calgary, Alberta, Canada.
  • van de Laar IMBH; Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Wilde AAM; AMC Heart Center, Department of Clinical and Experimental Cardiology, Academic Medical Center, Amsterdam, The Netherlands; Princess Al-Jawhara Al-Brahim Centre of Excellence in Research of Hereditary Disorders, Jeddah, Kingdom of Saudi Arabia. Electronic address: a.a.wilde@amc.uva.nl.
Heart Rhythm ; 16(2): 220-228, 2019 02.
Article em En | MEDLINE | ID: mdl-30170228
BACKGROUND: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an uncommon inherited arrhythmia disorder characterized by adrenergically evoked ventricular arrhythmias. Mutations in the cardiac calcium release channel/ryanodine receptor gene (RYR2) are identified in the majority of patients with CPVT. RyR2 is also the major RyR isoform expressed in the brain. OBJECTIVE: The purpose of this study was to estimate the prevalence of intellectual disability (ID) and other neurodevelopmental disorders (NDDs) in RYR2-associated CPVT (CPVT1) and to study the characteristics of these patients. METHODS: We reviewed the medical records of all CPVT1 patients from 12 international centers and analyzed the characteristics of all CPVT1 patients with concomitant NDDs. We functionally characterized the mutations to assess their response to caffeine activation. We did not correct for potential confounders. RESULTS: Among 421 CPVT1 patients, we identified 34 patients with ID (8%; 95% confidence interval 6%-11%). Median age at diagnosis was 9.3 years (interquartile range 7.0-14.5). Parents for 24 of 34 patients were available for genetic testing, and 13 of 24 (54%) had a de novo mutation. Severity of ID ranged from mild to severe and was accompanied by other NDDs in 9 patients (26%). Functionally, the ID-associated mutations showed a markedly enhanced response of RyR2 to activation by caffeine. Seventeen patients (50%) also had supraventricular arrhythmias. During median follow-up of 8.4 years (interquartile range 1.8-12.4), 15 patients (45%) experienced an arrhythmic event despite adequate therapy. CONCLUSION: Our study indicates that ID is more prevalent among CPVT1 patients (8%) than in the general population (1%-3%). This subgroup of CPVT1 patients reveals a malignant cardiac phenotype with marked supraventricular and ventricular arrhythmias.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Encéfalo / Taquicardia Ventricular / Canal de Liberação de Cálcio do Receptor de Rianodina / Transtornos do Neurodesenvolvimento / Miocárdio Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Child / Female / Humans / Male País/Região como assunto: America do norte / Europa Idioma: En Revista: Heart Rhythm Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Holanda

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Encéfalo / Taquicardia Ventricular / Canal de Liberação de Cálcio do Receptor de Rianodina / Transtornos do Neurodesenvolvimento / Miocárdio Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Child / Female / Humans / Male País/Região como assunto: America do norte / Europa Idioma: En Revista: Heart Rhythm Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Holanda